Barclays’s Evommune Inc EVMN Stock Holding History

Barclays’s Portfolio EVMN Stock Details EVMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38M	Buy	178,730 +176,752	+8,936%	+$4.11M	﹤0.01%	2245
2026 Q1	$45.5K	Buy	+1,978	New	+$44.7K	﹤0.01%	4356

Other funds holding EVMN

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Andera Partners Paris $206M AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Barclays's EVMN Position: Q2 2026 in Review

Barclays increased its Evommune Inc (EVMN) stake by 8,936% in Q2 2026, buying an estimated $4.11M and bringing the position to 178,730 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

Barclays first reported a position in EVMN in Q1 2026 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

Barclays held 178,730 shares of Evommune Inc worth $2.38M as of Q2 2026.
Barclays bought 176,752 Evommune Inc shares in Q2 2026, an estimated $4.11M.
Evommune Inc made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2245 holding.
Barclays first reported a position in Evommune Inc in Q1 2026 and has held it in 2 quarters since.
105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.